LGD-6972

SKU: orb1709263

Description

LGD-6972

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 1207989-09-0
• MW: 702.9
• Purity: 98.80% (May vary between batches)
• Formula: C₄₃H₄₆N₂O₅S
• SMILES: Cc1cc(C)c(c(C)c1)-c1ccc(NC(=O)[C@H](Cc2ccc(cc2)C(=O)NCCS(O)(=O)=O)c2ccc(cc2)-c2ccc(cc2)C(C)(C)C)cc1
• Target: Glucagon Receptor
• Solubility: DMSO:31 mg/mL (44.1 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (2.85 mM)

Bioactivity

• In Vivo:
  LGD-6972 is well tolerated at the doses tested without dose-related or clinically meaningful changes in clinical laboratory parameters. No subject experiences hypoglycaemia.LGD-6972 has linear plasma pharmacokinetics consistent with once daily dosing that is comparable in healthy and T2DM subjects. Dose-dependent decreases in fasting plasma glucose are observed in all groups with a maximum of 3.15 mM (56.8 mg/dL) on day 14 in T2DM subjects. LGD-6972 also reduces plasma glucose in the postprandial state. Dose-dependent increases in fasting plasma glucagon are observed, but glucagon levels decrease and insulin levels increase after an oral glucose load in T2DM subjects.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Inhibitor, inhibit, LGD6972, LGD-6972, LGD 6972, GCGR, hyperglycaemia, Glucagon Receptor, glucagon, GlucagonReceptor, glucagon receptor, cAMP, Diabetes

Compound Identifiers

PubChem CID

44625560